News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cordis Corporation (JNJ) Announces One-Year Results From the STROLL Trial


10/11/2012 10:09:27 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cordis Corporation today announced the presentation of the STROLL study results at the Late Breaking Clinical Trials session at VIVA 2012. Michael R. Jaff, DO, presented the results of the STROLL study (S.M.A.R.T.® Nitinol Self-Expanding Stent in the TReatment of Obstructive SuperficiaL FemoraL Artery Disease) on behalf of the study investigators. The STROLL study assessed the safety and efficacy of the S.M.A.R.T.® Nitinol Self-Expandable Stent System (S.M.A.R.T.® Stent) in treating patients with obstructive superficial femoral artery (SFA) disease. “The STROLL trial demonstrates one year patency rates of ~81% and a very low fracture rate,” said Dr. William A. Gray, Director of Endovascular Services, Cardiovascular Research Foundation, New York. “These outcomes both meet and exceed our expectations for patients with symptomatic disease of the superficial femoral artery.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES